Holdings
ADAR1 Capital Management, LLC
As of Sep 30, 2026, ADAR1 Capital Management, LLC reported 238 positions worth US$2.22B. Largest: Abivax SA, State Street SPDR S&P 500 ETF and Protagonist Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Abivax SA | 2.05M | US$203M | +246K | Sep 30, 2026 |
| State Street SPDR S&P 500 ETF | 178K | US$135M | new | Sep 30, 2026 |
| Protagonist Therapeutics, Inc. | 951K | US$134M | −9,460 | Sep 30, 2026 |
| Roivant Sciences Ltd. | 3.08M | US$113M | −77,482 | Sep 30, 2026 |
| Zai Lab Ltd. | 3.38M | US$89.1M | +12,330 | Sep 30, 2026 |
| Immunovant, Inc. | 2.12M | US$71.5M | −215K | Sep 30, 2026 |
| Xenon Pharmaceuticals Inc. | 1.16M | US$43.2M | +995K | Sep 30, 2026 |
| Denali Therapeutics Inc. | 2.07M | US$42.8M | +1.04M | Sep 30, 2026 |
| Alpha Architect 1-3 Month Box ETF | 337K | US$39.9M | new | Sep 30, 2026 |
| Septerna, Inc. | 974K | US$38.1M | +33,649 | Sep 30, 2026 |